RAPGEF3

Quality 0.50 · 1 view · Updated 2 months ago

Protein-coding gene in humans

title: "RAPGEF3" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public description: "Protein-coding gene in humans" topic_path: "uncategorized" source: "https://en.wikipedia.org/wiki/RAPGEF3" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Protein-coding gene in humans ::

Rap guanine nucleotide exchange factor 3 also known as exchange factor directly activated by cAMP 1 (EPAC1) or cAMP-regulated guanine nucleotide exchange factor I (cAMP-GEFI) is a protein that in humans is encoded by the RAPGEF3 gene.

As the name suggests, EPAC proteins (EPAC1 and EPAC2) are a family of intracellular sensors for cAMP, and function as nucleotide exchange factors for the Rap subfamily of RAS-like small GTPases.

History and discovery

Since the landmark discovery of the prototypic second messenger cAMP in 1957, three families of eukaryotic cAMP receptors have been identified to mediate the intracellular functions of cAMP. While protein kinase A (PKA) or cAMP-dependent protein kinase and cyclic nucleotide regulated ion channel (CNG and HCN) were initially unveiled in 1968 and 1985 respectively; EPAC genes were discovered in 1998 independently by two research groups. Kawasaki et al. identified cAMP-GEFI and cAMP-GEFII as novel genes enriched in brain using a differential display protocol and by screening clones with cAMP-binding motif. De Rooij and colleagues performed a database search for proteins with sequence homology to both GEFs for Ras and Rap1 and to cAMP-binding sites, which led to the identification and subsequent cloning of RAPGEF3 gene. The discovery of EPAC family cAMP sensors suggests that the complexity and possible readouts of cAMP signaling are much more elaborate than previously envisioned. This is due to the fact that the net physiological effects of cAMP entail the integration of EPAC- and PKA-dependent pathways, which may act independently, converge synergistically, or oppose each other in regulating a specific cellular function.

Gene

Human RAPGEF3 gene is present on chromosome 12 (12q13.11: 47,734,367-47,771,041). Out of the many predicted transcript variants, three that are validated in the NCBI database include transcript variant 1 (6,239 bp), 2 (5,773 bp) and 3 (6,003 bp). While variant 1 encodes for EPAC1a (923 amino acids), both variant 2 and 3 encode EPAC1b (881 amino acids).

Protein family

In mammals, the EPAC protein family contains two members: EPAC1 (this protein) and EPAC2 (RAPGEF4). They further belong to a more extended family of Rap/Ras-specific GEF proteins that also include C3G (RAPGEF1), PDZ-GEF1 (RAPGEF2), PDZ-GEF2 (RAPGEF6), Repac (RAPGEF5), CalDAG-GEF1 (ARHGEF1), CalDAG-GEF3 (ARHGEF3), PLCε1 (PLCE1) and RasGEF1A, B, C.

Protein structure and mechanism of activation

EPAC proteins consist of two structural lobes/halves connected by the so-called central "switchboard" region. The N terminal regulatory lobe is responsible for cAMP binding while the C-terminal lobe contains the nucleotide exchange factor activity. At the basal cAMP-free state, EPAC is kept in an auto-inhibitory conformation, in which the N-terminal lobe folds on top of the C-terminal lobe, blocking the active site. Binding of cAMP to EPAC induces a hinge motion between the regulatory and catalytic halves. As a consequence, the regulatory lobe moves away from catalytic lobe, freeing the active site. In addition, cAMP also prompts conformational changes within the regulatory lobe that lead to the exposure of a lipid binding motif, allowing the proper targeting of EPAC1 to the plasma membrane. Entropically favorable changes in protein dynamics have also been implicated in cAMP mediated EPAC activation.

Tissue distribution and cellular localization

Human and mice EPAC1 mRNA expression is rather ubiquitous. As per Human Protein Atlas documentation, EPAC1 mRNA is detectable in all normal human tissues. Further, medium to high levels of corresponding protein are also measureable in more than 50% of the 80 tissue samples analyzed. In mice, high levels of EPAC1 mRNA are detected in kidney, ovary, skeletal muscle, thyroid and certain areas of the brain.

EPAC1 is a multifunctional protein whose cellular functions are tightly regulated in spatial and temporal manners. EPAC1 is localized to various subcellular locations during different stages of the cell cycle. Through interactions with an array of cellular partners, EPAC1 has been shown to form discrete signalsomes at plasma membrane, nuclear-envelope, and cytoskeleton, where EPAC1 regulates numerous cellular functions.

Clinical relevance

Studies based on genetically engineered mouse models of EPAC1 have provided valuable insights into understanding the in vivo functions of EPAC1 under both physiological and pathophysiological conditions. Overall, mice deficient of EPAC1 or both EPAC1 and EPAC2 appear relatively normal without major phenotypic defects. These observations are consistent with the fact that cAMP is a major stress response signal not essential for survival. This makes EPAC1 an attractive target for therapeutic intervention as the on-target toxicity of EPAC-based therapeutics will likely be low. Up to date, genetic and pharmacological analyses of EPAC1 in mice have revealed that EPAC1 plays important roles in cardiac stresses and heart failure, leptin resistance and energy homeostasis, chronic pain, infection, cancer metastasis, metabolism and secondary hemostasis. Interestingly, EPAC1 deficient mice have prolonged clotting time and fewer, younger, larger and more agonist-responsive blood platelets. EPAC1 is not present in mature platelets, but is required for normal megakaryopoiesis and the subsequent expression of several important proteins involved in key platelets functions.

Pharmacological agonists and antagonists

There have been significant interests in discovering and developing small modulators specific for EPAC proteins for better understanding the functions of EPAC mediated cAMP signaling, as well as for exploring the therapeutic potential of targeting EPAC proteins. Structure-based design targeting the key difference between the cAMP binding sites of EPAC and PKA led to the identification of a cAMP analogue, 8-pCPT-2'-O-Me-cAMP that is capable of selectively activate EPAC1. Further modifications allowed the development of more membrane permeable and metabolically stable EPAC-specific agonists.

A high throughput screening effort resulted in the discovery of several novel EPAC specific inhibitors (ESIs), among which two ESIs act as EPAC2 selective antagonists with negligible activity towards EPAC1. Another ESI, CE3F4, with modest selectivity for EPAC1 over EPAC2, has also been reported. The discovery of EPAC specific antagonists represents a research milestone that allows the pharmacological manipulation of EPAC activity. In particular, one EPAC antagonist, ESI-09, with excellent activity and minimal toxicity in vivo, has been shown to be a useful pharmacological tool for probing physiological functions of EPAC proteins and for testing therapeutic potential of targeting EPAC in animal disease models.

Notes

| wikidate = 2015 | journal = Gene | Q = Q28608179

References

References

  1. "Entrez".
  2. (December 1998). "Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP". Nature.
  3. (December 1998). "A family of cAMP-binding proteins that directly activate Rap1". Science.
  4. (March 2002). "Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation". The Journal of Biological Chemistry.
  5. (July 2008). "Epac and PKA: a tale of two intracellular cAMP receptors". Acta Biochimica et Biophysica Sinica.
  6. (September 2008). "EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation". Proceedings of the National Academy of Sciences of the United States of America.
  7. "Ensembl".
  8. (February 2006). "Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state". Nature.
  9. (July 2000). "Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs". The Journal of Biological Chemistry.
  10. (June 2003). "Communication between the regulatory and the catalytic region of the cAMP-responsive guanine nucleotide exchange factor Epac". The Journal of Biological Chemistry.
  11. (September 2008). "Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B". Nature.
  12. (August 2009). "Mechanism of Epac activation: structural and functional analyses of Epac2 hinge mutants with constitutive and reduced activities". The Journal of Biological Chemistry.
  13. (May 2011). "Mechanism of intracellular cAMP sensor Epac2 activation: cAMP-induced conformational changes identified by amide hydrogen/deuterium exchange mass spectrometry (DXMS)". The Journal of Biological Chemistry.
  14. (March 2012). "cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane". Proceedings of the National Academy of Sciences of the United States of America.
  15. (August 2009). "Dynamically driven ligand selectivity in cyclic nucleotide binding domains". The Journal of Biological Chemistry.
  16. (December 2011). "Role of dynamics in the autoinhibition and activation of the exchange protein directly activated by cyclic AMP (EPAC)". The Journal of Biological Chemistry.
  17. "Human Protein Altas".
  18. (July 2002). "Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP". The Journal of Biological Chemistry.
  19. (May 2009). "Direct spatial control of Epac1 by cyclic AMP". Molecular and Cellular Biology.
  20. (November 2010). "Spatial regulation of cyclic AMP-Epac1 signaling in cell adhesion by ERM proteins". Molecular and Cellular Biology.
  21. (January 2011). "Radixin assembles cAMP effectors Epac and PKA into a functional cAMP compartment: role in cAMP-dependent cell proliferation". The Journal of Biological Chemistry.
  22. (September 2005). "The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways". Nature.
  23. (October 2011). "Regulating Rap small G-proteins in time and space". Trends in Cell Biology.
  24. (August 2010). "The interaction of Epac1 and Ran promotes Rap1 activation at the nuclear envelope". Molecular and Cellular Biology.
  25. (October 2005). "Interplay between exchange protein directly activated by cAMP (Epac) and microtubule cytoskeleton". Molecular BioSystems.
  26. (March 2008). "Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function". Molecular Biology of the Cell.
  27. (January 2011). "AKAP9 regulation of microtubule dynamics promotes Epac1-induced endothelial barrier properties". Blood.
  28. (April 2008). "Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy". Circulation Research.
  29. (June 2014). "Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses". The Journal of Clinical Investigation.
  30. (March 2011). "Induction of leptin resistance by activation of cAMP-Epac signaling". Cell Metabolism.
  31. (March 2013). "Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1". Molecular and Cellular Biology.
  32. (February 2014). "Cyclic AMP sensor EPAC proteins and energy homeostasis". Trends in Endocrinology and Metabolism.
  33. (2013). "A role for Piezo2 in EPAC1-dependent mechanical allodynia". Nature Communications.
  34. (December 2013). "Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain". The Journal of Clinical Investigation.
  35. (November 2013). "Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses". Proceedings of the National Academy of Sciences of the United States of America.
  36. (April 2014). "Blocking of exchange proteins directly activated by cAMP leads to reduced replication of Middle East respiratory syndrome coronavirus". Journal of Virology.
  37. (February 2015). "Pharmacological inhibition and genetic knockdown of exchange protein directly activated by cAMP 1 reduce pancreatic cancer metastasis in vivo". Molecular Pharmacology.
  38. (January 2014). "Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways". The Journal of Clinical Investigation.
  39. (August 2017). "Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression". Scientific Reports.
  40. (November 2002). "A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK". Nature Cell Biology.
  41. (September 2003). "cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension". The Journal of Biological Chemistry.
  42. (April 2008). "Cyclic nucleotide analogs as probes of signaling pathways". Nature Methods.
  43. (September 2008). "8-pCPT-2'-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue". ChemBioChem.
  44. (January 2008). "Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors". Cellular Signalling.
  45. (January 2015). "Structure-guided design of selective Epac1 and Epac2 agonists". PLOS Biology.
  46. (2012). "A fluorescence-based high-throughput assay for the discovery of exchange protein directly activated by cyclic AMP (EPAC) antagonists". PLOS ONE.
  47. (November 2012). "Isoform-specific antagonists of exchange proteins directly activated by cAMP". Proceedings of the National Academy of Sciences of the United States of America.
  48. (January 2013). "A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion". Molecular Pharmacology.
  49. (December 2012). "Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac". The Journal of Biological Chemistry.
  50. (March 2015). "Biochemical and pharmacological characterizations of ESI-09 based EPAC inhibitors: defining the ESI-09 "therapeutic window"". Scientific Reports.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::